Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient rate of accrual

Conditions

Graft vs Host Disease

Interventions

BIOLOGICAL: Begelomab
BIOLOGICAL: Conventional Second-line Treatment

Sponsor

Adienne SA

Collaborators

[object Object]